Bulletins
Filter by category:
AdministrationAdverse drug reactionsComplementary and Alternative Medicines (CAMs)COVID-19Drug comparisonsInteractionsNew medicineOtherPharmacokineticPregnancy/Breastfeeding

Drug Interactions with nirmatrelvir-ritonavir (Paxlovid®) - August 4, 2022
This page was last updated: December 2024
Ritonavir increases (boosts) the concentration of nirmatrelvir by inhibiting its clearance by CYP3A enzymes. This also increases the concentration of other drugs metabolised by CYP3A. The tables below provide guidance on adjusting doses of patients’ ...



Therapeutic Drug Monitoring of Aminoglycosides - May 25, 2022
Aminoglycosides (gentamicin, tobramycin and amikacin) are bactericidal antibiotics used to treat infections caused by Gram-negative organisms. Therapeutic drug monitoring is recommended to ensure adequate dosing and prevent adverse effects such as nephrotoxicity and ototoxicity. Aminoglycosides d...



Quality of complementary and alternative products - October 15, 2021
Complementary and alternative products (CAPs) include: herbals (dried plant materials, plant extracts), dietary supplements, probiotics and homeopathic products. For most CAPs sold in New Zealand, adherence to the Code of Good Manufacturing Practice (GMP) is voluntary and regulatory approval is n...



Gluten and Lactose in Medicines - September 1, 2021
Gluten and lactose may be present in medicines as excipients. Excipients are intended to be pharmacologically inactive ingredients, and include binders, absorbents, protectants and colouring agents. Some patients need to, or choose to, avoid gluten or lactose. This bulletin summarises what to con...



Empagliflozin and dulaglutide in type 2 diabetes - April 6, 2021
NZ is funding two medicines in new classes for the treatment of type 2 diabetes.1 These will be second line options after metformin, and favoured for patients at high risk of cardiovascular or renal complications. They are subject to special authority criteria.1-3 Empagliflozin, a sodium-glucose ...



Activation of prodrugs affected by CYP induction/inhibition - February 26, 2021
Definition
Prodrugs are inactive precursors designed to be converted to an active form after administration. This is to overcome poor physio-chemical or pharmacokinetic properties of the active drug.
Prodrugs – methods of activation
Prodrugs are activated by a variety of mechanisms including...



Metronidazole in Pregnancy and Breastfeeding - August 27, 2020
Metronidazole in Pregnancy and Breastfeeding
There is inconsistent advice regarding the use of metronidazole in pregnant and breastfeeding women. Historically, its safety in pregnancy and breastfeeding has been controversial due to data from animal studies showing that metronidazole is potential...